Bora Biologics Announces Strategic Collaboration to Accelerate Key CMC Development of DotBio’s Tri-Specific Antibody to Treat Cancer
TAIPEI, TAIWAN – January 9th, 2025 – Bora Biologics, a fast-growing division of leading contract development and manufacturing organization (CDMO), Bora Pharmaceuticals, today announced that it will support DotBio, a Singaporean biopharmaceutical company specializing in next-generation antibody therapies, in the development and manufacturing of DotBio’s lead asset, a novel tri-specific antibody, code name DB007, against undisclosed cancer targets.
Bora will support the development of DotBio’s lead asset, including its chemistry, manufacturing and controls (CMC) strategy, through to clinical development from its 48,400-square-foot (4,500-square-meter) centre-of-excellence in Zhubei, Taiwan.
“Bora Biologics offers a tailored development and manufacturing plan that provides end-to-end support for our client’s development programs,” commented Bobby Sheng, Chairman and CEO of Bora Group. “With operations up and running in Zhubei, Bora’s team of experts are ready to deliver high-yield processes together with the sophisticated program management capabilities necessary to successfully develop even the most challenging molecules.”
Ignacio Asial, Ph.D., Founder and CEO of DotBio said, “We chose Bora Biologics as our development partner because of its expertise in early-phase biologics development and solid track record in high-yield manufacturing of multi-specific antibody molecules. Bora’s early-clinical manufacturing facilities in Taiwan align perfectly with our current IND-development stage, while their large-scale, commercial-stage manufacturing and fill-and-finish facilities in the United States will support our goal to treat patients globally. I am thrilled to be working hand-in-hand with one of the best CDMO partners in Asia.”
Bora Biologics’ facility in Zhubei provides early-stage discovery research support, lead candidate screening, in vitro assays, and biochemical/physical assays, as well as preparation and purification of the most complex proteins, and monoclonal, bispecific and multi-specific antibodies and other recombinant proteins for research purposes.
About Bora Biologics
Bora Biologics Co., Ltd. is a fast-growing biologics Contract Development and Manufacturing Organization (CDMO) in Taiwan with a track record of more than 70 batches produced in its cGMP manufacturing plant at 100% success rate continuously since 2014. Bora Biologics provides flexible and integrated solutions based on a scalable platform technology that supports superior product quality and yield for mAbs, Bi-Specifics, Fc Fusion Proteins, Enzymes, Recombinant Proteins, and Antigens for Vaccines among others. Bora Bio is dedicated to becoming a global leader in biologic manufacturing by offering its clients the best quality, efficiency, and reliability. Bora Biologics intends to merge with Tanvex in the first quarter 2025.
About DotBio Pte. Ltd.
DotBio is an innovative biopharmaceutical company dedicated to advancing next-generation antibody therapies for more effective treatments. Utilizing a rapid prototyping approach, DotBio develops multi-functional and intracellular antibodies that combine synergistic activities, optimal architectures, and unique mechanisms of action. The company operates a versatile platform with a growing portfolio, including various target-specific DotBody modules, the out-licensed JS207 program currently in clinical trials, and multiple multi-specific antibody candidates in preclinical development. For more information about DotBio, please visit www.dotbio.com.
